News
At Cell-Easy, we provide end-to-end GMP manufacturing services for advanced therapy medicinal products (ATMPs), with a strong focus on compliance, scalability, and reliability.
We help biotech and pharma companies bring innovative cell therapies from the lab to the clinic by combining high-quality starting material sourcing, robust process development, and clinical-grade GMP production that meets international standards (MHRA, ANSM, EMA, FDA readiness).
Whether you need early clinical batches or large-scale production, our tailored solutions optimize your process, minimize risks, and accelerate time-to-clinic.
EMERCell & Cell-Easy sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001
Learn more: EMERCell & Cell-Easy sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001EMERCell & Cell-Easy sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001 Emercell has selected Cell-Easy as a long-term CDMO partner for the scale-up and manufacturing operations of its allogeneic NK cell-based product, with the objective to enter clinical phase in 2023. Emercell has signed a strategic agreement with Cell-Easy specialized in the…
Cell-Easy Launches OPTI-STEM for Cell Therapy Access
Learn more: Cell-Easy Launches OPTI-STEM for Cell Therapy AccessCell-Easy Launches OPTI-STEM for Cell Therapy Access The OPTI-STEM consortium led by CDMO Cell-Easy receives €7M from the French government and Bpifrance and €800,000 from the Occitanie Region to democratize access to cell therapy in France and Europe The OPTI-STEM project aims to optimize the production of MSCs in order to democratize access to them…